-- 在默克公司 (MRK) 的 belzutifan 在 Litespark-012 試驗中 3 期臨床試驗失敗後，Arcus Biosciences (RCUS) 的股價獲得了有利的佈局。 Wedbush Securities 表示，默克的試驗結果並不代表 Arcus 的 casdatifan 也面臨同樣的問題，並凸顯了 casdatifan 在透明細胞腎細胞癌 (RCC) 治療中的獨特優勢。 該券商在周二的一份報告中指出，默克的數據不會影響 Arcus 的無 TKI 一線治療策略，casdatifan 憑藉更優化的研發方案和比 belzutifan 更強的療效，仍然值得繼續持有。 Wedbush 也表示，Arcus 的 domvanalimab 計畫終止後股價近期的疲軟，為即將公佈的臨床數據創造了一個極具吸引力的買入時機，進一步鞏固了該股的良好前景。 該公司重申了對該股的「跑贏大盤」評級和每股 41 美元的目標價。
Price: $23.31, Change: $+0.57, Percent Change: +2.51%
Joyvio Food's (SHE:300268) attributable loss narrowed 96% to 7.84 million yuan in the first quarter from 180.9 million yuan in the year-ago period, according to a Monday filing by parent company Legend Holdings (HKG:3396) with the Hong Kong bourse.Loss per share at the Chinese agricultural products company came in at 0.0450 yuan compared with 1.0385 yuan in the prior-year period.Revenue declined 71% to 194.3 million yuan from 677.5 million yuan in the year-ago period.
Shengyi Technology (SHA:600183) posted full-year attributable net profit of 3.33 billion yuan in 2025, up 92% from 1.74 billion yuan in 2024.Earnings per share rose to 1.38 yuan from 0.73 yuan, according to a filing with the Shanghai bourse over the weekend.The electronic components manufacturer's revenue climbed 39% year over year to 28.4 billion yuan from 20.4 billion yuan.
East Money Information (SHE:300059) posted first-quarter attributable net profit of 3.74 billion yuan, up 38% from 2.72 billion yuan the previous year.Earnings per share rose to 0.2364 yuan from 0.1719 yuan, according to a filing with the Shenzhen bourse over the weekend.The financial services provider's operating revenue climbed 44% year over year to 5.03 billion yuan from 3.49 billion yuan.